Systematic review and meta-analysis of residential radon and lung cancer in never-smokers.


Journal

European respiratory review : an official journal of the European Respiratory Society
ISSN: 1600-0617
Titre abrégé: Eur Respir Rev
Pays: England
ID NLM: 9111391

Informations de publication

Date de publication:
31 Mar 2021
Historique:
received: 16 07 2020
accepted: 28 10 2020
entrez: 4 2 2021
pubmed: 5 2 2021
medline: 25 11 2021
Statut: epublish

Résumé

Globally, radon is the leading risk factor for lung cancer in never-smokers (LCINS). In this study, we systematically reviewed and meta-analysed the evidence of the risk of LCINS associated with residential radon exposure. Medline and Embase databases were searched using predefined inclusion and exclusion criteria to identify relevant studies published from 1 January 1990 to 5 March 2020 focused on never-smokers. We identified four pooled collaborative studies (incorporating data from 24 case-control studies), one case-control study and one cohort study for systematic review. Meta-analysis was performed on the results of the four pooled studies due to different measures of effect and outcome reported in the cohort study and insufficient information reported for the case-control study. In a Risk estimates of lung cancer from residential radon exposure were pooled in the meta-analysis for 2341 never-smoker cases, 8967 never-smoker controls, 9937 ever-smoker cases and 12 463 ever-smoker controls. Adjusted excess relative risks (aERRs) per 100 Bq·m This study provided quantified risk estimates for lung cancer from residential radon exposure among both never-smokers and ever-smokers. Among never-smokers in radon-prone areas, men were at higher risk of lung cancer than women.

Sections du résumé

BACKGROUND BACKGROUND
Globally, radon is the leading risk factor for lung cancer in never-smokers (LCINS). In this study, we systematically reviewed and meta-analysed the evidence of the risk of LCINS associated with residential radon exposure.
METHODS METHODS
Medline and Embase databases were searched using predefined inclusion and exclusion criteria to identify relevant studies published from 1 January 1990 to 5 March 2020 focused on never-smokers. We identified four pooled collaborative studies (incorporating data from 24 case-control studies), one case-control study and one cohort study for systematic review. Meta-analysis was performed on the results of the four pooled studies due to different measures of effect and outcome reported in the cohort study and insufficient information reported for the case-control study. In a
RESULTS RESULTS
Risk estimates of lung cancer from residential radon exposure were pooled in the meta-analysis for 2341 never-smoker cases, 8967 never-smoker controls, 9937 ever-smoker cases and 12 463 ever-smoker controls. Adjusted excess relative risks (aERRs) per 100 Bq·m
CONCLUSION CONCLUSIONS
This study provided quantified risk estimates for lung cancer from residential radon exposure among both never-smokers and ever-smokers. Among never-smokers in radon-prone areas, men were at higher risk of lung cancer than women.

Identifiants

pubmed: 33536262
pii: 30/159/200230
doi: 10.1183/16000617.0230-2020
pmc: PMC9488946
pii:
doi:

Substances chimiques

Radon Q74S4N8N1G

Types de publication

Journal Article Meta-Analysis Review Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright ©ERS 2021.

Déclaration de conflit d'intérêts

Conflict of interest: E.S. Cheng has no conflicts of interest to declare. Conflict of interest: S. Egger has nothing to disclose. Conflict of interest: S. Hughes has nothing to disclose. Conflict of interest: M. Weber reports other support from Cancer Australia and Australian Department of Health, outside the submitted work. Conflict of interest: J. Steinberg has nothing to disclose. Conflict of interest: B. Rahman has nothing to disclose. Conflict of interest: H. Worth has nothing to disclose. Conflict of interest: A. Ruano-Ravina has nothing to disclose. Conflict of interest: P. Rawstorne has nothing to disclose. Conflict of interest: X.Q. Yu has nothing to disclose.

Références

Am J Epidemiol. 2002 Mar 15;155(6):554-64
pubmed: 11882529
Cent Eur J Public Health. 2001 Aug;9(3):150-3
pubmed: 11505739
J Toxicol Environ Health A. 2006 Apr;69(7):533-97
pubmed: 16608828
J Natl Cancer Inst. 1997 Jan 1;89(1):49-57
pubmed: 8978406
Scand J Work Environ Health. 2006;32 Suppl 1:1-83
pubmed: 16538937
J Clin Epidemiol. 2016 Jan;69:225-34
pubmed: 26092286
Health Phys. 1996 Aug;71(2):185-9
pubmed: 8690601
Am J Public Health. 1999 Jul;89(7):1042-8
pubmed: 10394313
Int J Environ Res Public Health. 2020 Feb 24;17(4):
pubmed: 32102460
Eur Respir J. 2014 Oct;44(4):994-1001
pubmed: 25034571
Acta Oncol. 2017 Jul;56(7):931-935
pubmed: 28514931
Epidemiology. 2004 Nov;15(6):709-16
pubmed: 15475720
Health Phys. 1990 Dec;59(6):807-17
pubmed: 2228608
Crit Rev Oncol Hematol. 2020 Apr;148:102895
pubmed: 32062313
Epidemiology. 2005 Mar;16(2):137-45
pubmed: 15703527
Ann Oncol. 2001 Oct;12(10):1341-51
pubmed: 11762803
J Natl Cancer Inst. 2006 May 17;98(10):691-9
pubmed: 16705123
IARC Monogr Eval Carcinog Risks Hum. 1988;43:39-171
pubmed: 3065211
Int J Cancer. 2004 Mar;109(1):132-7
pubmed: 14735479
Am J Epidemiol. 2002 Sep 15;156(6):548-55
pubmed: 12226002
J Toxicol Environ Health A. 2006 Apr;69(7):599-631
pubmed: 16608829
Eur Respir J. 2016 Nov;48(5):1462-1470
pubmed: 27799390
Int J Radiat Biol. 2019 Mar;95(3):354-359
pubmed: 30496022
Int J Mol Sci. 2013 Jul 05;14(7):14024-63
pubmed: 23880854
Eur J Cancer. 2012 Jun;48(9):1299-311
pubmed: 22464348
Bull World Health Organ. 2003;81(10):732-8
pubmed: 14758433
Int J Epidemiol. 2002 Feb;31(1):86-7
pubmed: 11914300
J Natl Cancer Inst. 1990 Jun 20;82(12):1025-30
pubmed: 2348467
Environ Res. 2019 May;172:713-718
pubmed: 30903971
BMJ. 2005 Jan 29;330(7485):223
pubmed: 15613366
Cancer Epidemiol Biomarkers Prev. 2012 Jun;21(6):951-8
pubmed: 22539606
Future Oncol. 2011 Oct;7(10):1195-211
pubmed: 21992731
Br J Cancer. 1998 Aug;78(3):394-408
pubmed: 9703290
Lung Cancer. 2010 Feb;67(2):144-50
pubmed: 19464070
J Clin Oncol. 2006 May 20;24(15):2245-51
pubmed: 16710022
Am J Epidemiol. 2000 Jun 1;151(11):1091-102
pubmed: 10873134
Cancer Res. 1990 Oct 15;50(20):6520-4
pubmed: 2208111
Int J Radiat Biol. 2015 Aug;91(8):605-10
pubmed: 25968558
J Natl Cancer Inst. 1994 Dec 21;86(24):1829-37
pubmed: 7990157
Oncology (Williston Park). 2010 Jan;24(1):29-35
pubmed: 20187318
J Toxicol Environ Health A. 2006 Apr;69(7):633-54
pubmed: 16608830
Am J Epidemiol. 2001 Jan 1;153(1):42-52
pubmed: 11159146
J Thorac Oncol. 2016 Sep;11(9):1384-6
pubmed: 27565403
Eur Respir J. 2016 Sep;48(3):852-60
pubmed: 27390281
Int J Cancer. 2019 Apr 15;144(8):1941-1953
pubmed: 30350310
Syst Rev. 2015 Jan 01;4:1
pubmed: 25554246
Appl Radiat Isot. 2010 Apr-May;68(4-5):816-20
pubmed: 19822441
Cancer Lett. 2018 Jul 10;426:57-62
pubmed: 29654890
Environ Sci Technol. 1995 May 1;29(5):1359-64
pubmed: 22192033
Ann Occup Environ Med. 2016 Mar 09;28:11
pubmed: 26962458
Radiat Prot Dosimetry. 2011 May;145(2-3):243-7
pubmed: 21498865
N Engl J Med. 1994 Jan 20;330(3):159-64
pubmed: 8264737
Int J Cancer. 2005 May 10;114(6):983-91
pubmed: 15645434
CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108
pubmed: 15761078
J Radiat Res. 2013 Jul 1;54(4):597-610
pubmed: 23297318
J Natl Cancer Inst. 1995 Jun 7;87(11):817-27
pubmed: 7791231
Radiat Prot Dosimetry. 2003;104(4):315-9
pubmed: 14579887
J Natl Cancer Inst. 1996 Jul 17;88(14):966-72
pubmed: 8667427
Radiat Prot Dosimetry. 2008;128(2):169-79
pubmed: 17611199
Health Phys. 1992 Aug;63(2):179-86
pubmed: 1399616
Epidemiology. 2003 Sep;14(5):559-68
pubmed: 14501271
Cancer Epidemiol Biomarkers Prev. 2011 Mar;20(3):438-48
pubmed: 21212062
J Radiat Res. 2018 Mar 1;59(2):149-163
pubmed: 29186473
Epidemiology. 2001 Jul;12(4):396-404
pubmed: 11416777
Environ Res. 2020 Oct;189:109968
pubmed: 32736146
Radiat Environ Biophys. 2019 Mar;58(1):39-47
pubmed: 30535840
Eur Respir J. 2017 Nov 9;50(5):
pubmed: 29122919
Am J Epidemiol. 1994 Aug 15;140(4):310-22
pubmed: 8059766
Arch Bronconeumol. 2017 Sep;53(9):475-476
pubmed: 28237066
Nat Rev Cancer. 2007 Oct;7(10):778-90
pubmed: 17882278
Int J Epidemiol. 1999 Feb;28(1):1-9
pubmed: 10195657
Environ Health Perspect. 2012 Nov;120(11):1503-11
pubmed: 22728254

Auteurs

Elvin S Cheng (ES)

Cancer Research Division, Cancer Council NSW, Sydney, Australia elvin.cheng@nswcc.org.au.
School of Public Health, Faculty of Medicine and Health, University of Sydney, Sydney, Australia.

Sam Egger (S)

Cancer Research Division, Cancer Council NSW, Sydney, Australia.

Suzanne Hughes (S)

Cancer Research Division, Cancer Council NSW, Sydney, Australia.
School of Public Health, Faculty of Medicine and Health, University of Sydney, Sydney, Australia.

Marianne Weber (M)

Cancer Research Division, Cancer Council NSW, Sydney, Australia.
School of Public Health, Faculty of Medicine and Health, University of Sydney, Sydney, Australia.

Julia Steinberg (J)

Cancer Research Division, Cancer Council NSW, Sydney, Australia.
School of Public Health, Faculty of Medicine and Health, University of Sydney, Sydney, Australia.

Bayzidur Rahman (B)

School of Public Health and Community Medicine, University of New South Wales, Sydney, Australia.

Heather Worth (H)

School of Public Health and Community Medicine, University of New South Wales, Sydney, Australia.

Alberto Ruano-Ravina (A)

Dept of Preventive Medicine and Public Health, University of Santiago de Compostela, Santiago de Compostela, Spain.
Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP, Consorcio de Investigación Biomédica en Red de Epidemiología y Salud Pública), Madrid, Spain.
Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain.

Patrick Rawstorne (P)

School of Public Health and Community Medicine, University of New South Wales, Sydney, Australia.
Equal contribution as last author.

Xue Qin Yu (XQ)

Cancer Research Division, Cancer Council NSW, Sydney, Australia.
School of Public Health, Faculty of Medicine and Health, University of Sydney, Sydney, Australia.
Equal contribution as last author.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH